Literature DB >> 23701387

Osteopontin: Versatile modulator of liver diseases.

Sumiko Nagoshi1.   

Abstract

Osteopontin (OPN) is a multifunctional protein, involved in pathological conditions including inflammation, immunity, angiogenesis, fibrosis and cancer progression in various tissues. Hepatic inflammation and fibrosis induced by feeding with a diet deficient in methionine and choline (MCD diet) were markedly attenuated in OPN knockout mice when compared with wild-type mice in the model of non-alcoholic steatohepatitis (NASH). Hepatic cholangiocytes, myofibroblastic stellate cells and natural killer T cells were suggested to secret OPN in mice fed an MCD diet. Plasma and hepatic OPN levels were significantly higher in patients with NASH with advanced fibrosis than in those with early fibrosis. Hepatic OPN mRNA level was correlated with hepatic neutrophil infiltration and fibrosis in patients with alcoholic liver diseases. In those with hepatocellular carcinoma (HCC), OPN levels in plasma and HCC were prognostic factors after liver resection or transplantation. Downregulation of OPN inhibited tumor growth and lung metastasis in nude mice implanted with HCC cells. The single nucleotide polymorphism in the promoter region of the OPN gene was shown to be associated with activity of hepatitis in chronic hepatitis C patients, prognosis in patients with HCC, and growth and lung metastasis of HCC xenografts in nude mice. OPN was reported to be a downstream effecter of Hedgehog pathway, which modulates hepatic fibrosis and carcinogenesis. This review focuses on the roles of OPN in hepatic inflammation, fibrosis and cancer progression. Further elucidation of cellular interactions and molecular mechanisms associated with OPN actions may contribute to development of novel strategies for treatment of the liver diseases.
© 2013 The Japan Society of Hepatology.

Entities:  

Keywords:  alcoholic liver disease; hepatocellular carcinoma; liver fibrosis; non-alcoholic fatty liver disease; osteopontin

Year:  2013        PMID: 23701387     DOI: 10.1111/hepr.12166

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  47 in total

1.  Inhibition of hedgehog signaling ameliorates hepatic inflammation in mice with nonalcoholic fatty liver disease.

Authors:  Hyunjoo Kwon; Kyoungsub Song; Chang Han; Weina Chen; Ying Wang; Srikanta Dash; Kyu Lim; Tong Wu
Journal:  Hepatology       Date:  2015-12-18       Impact factor: 17.425

2.  Modeling toxicodynamic effects of trichloroethylene on liver in mouse model of autoimmune hepatitis.

Authors:  Kathleen M Gilbert; Brad Reisfeld; Todd J Zurlinden; Meagan N Kreps; Stephen W Erickson; Sarah J Blossom
Journal:  Toxicol Appl Pharmacol       Date:  2014-07-12       Impact factor: 4.219

Review 3.  Comparative analysis of gene expression profiles of OPN signaling pathway in four kinds of liver diseases.

Authors:  Gaiping Wang; Shasha Chen; Congcong Zhao; Xiaofang Li; Weiming Zhao; Jing Yang; Cuifang Chang; Cunshuan Xu
Journal:  J Genet       Date:  2016-09       Impact factor: 1.166

4.  Serum osteopontin is a predictor of prognosis for HBV-associated acute-on-chronic liver failure.

Authors:  Longgen Liu; Jianchun Lu; Chunyan Ye; Lin Lin; Shuqin Zheng; Hongyu Zhang; Qing Lan; Yuan Xue
Journal:  Biomed Rep       Date:  2017-12-13

Review 5.  Invasive and non-invasive assessment of portal hypertension.

Authors:  Jonathan Chung-Fai Leung; Thomson Chi-Wang Loong; James Pang; Jeremy Lok Wei; Vincent Wai-Sun Wong
Journal:  Hepatol Int       Date:  2017-03-30       Impact factor: 6.047

Review 6.  New advances in molecular mechanisms and emerging therapeutic targets in alcoholic liver diseases.

Authors:  Jessica A Williams; Sharon Manley; Wen-Xing Ding
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

7.  Biliary fibrosis drives liver repopulation and phenotype transition of transplanted hepatocytes.

Authors:  Mladen I Yovchev; Joseph Locker; Michael Oertel
Journal:  J Hepatol       Date:  2016-02-05       Impact factor: 25.083

8.  Osteopontin is up-regulated in chronic hepatitis C and is associated with cellular permissiveness for hepatitis C virus replication.

Authors:  Steve S Choi; Lee C Claridge; Ravi Jhaveri; Marzena Swiderska-Syn; Paul Clark; Ayako Suzuki; Thiago A Pereira; Zhiyong Mi; Paul C Kuo; Cynthia D Guy; Fausto E L Pereira; Anna Mae Diehl; Keyur Patel; Wing-Kin Syn
Journal:  Clin Sci (Lond)       Date:  2014-06       Impact factor: 6.124

9.  miR-21 Inhibition Reduces Liver Fibrosis and Prevents Tumor Development by Inducing Apoptosis of CD24+ Progenitor Cells.

Authors:  Jing Zhang; Jingjing Jiao; Silvia Cermelli; Kyle Muir; Kwang Hwa Jung; Ruhai Zou; Asif Rashid; Mihai Gagea; Sonya Zabludoff; Raghu Kalluri; Laura Beretta
Journal:  Cancer Res       Date:  2015-03-13       Impact factor: 12.701

10.  Osteopontin: a new player in regulating hepatic ductular reaction and hepatic progenitor cell responses during chronic liver injury.

Authors:  Mario Strazzabosco; Luca Fabris; Emanuele Albano
Journal:  Gut       Date:  2014-07-23       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.